Economics of Genomic Testing for Women with Breast Cancer | Diaceutics

Economics of Genomic Testing for Women with Breast Cancer

February 22nd, 2014

Jordan Clark

Jordan Clark of Diaceutics comments on the American Journal of Managed Care article ‘Economics of Genomic Testing for Women With Breast Cancer’ and highlights that personalized medicine is being held back by the unwillingness of payers to reimburse genomic testing.

Robert D Lieberthal, PhD, from the Jefferson Population Health Continuing Professional Education Collaborative, describes in the American Journal of Managed Care ( what he believes to be the first structured review of the economics of breast cancer care.  The NIH estimates that the annual financial burden of breast cancer is around $14 billion. Lieberthal’s excellent review highlights what is generally agreed, namely that genomic testing and personalized medicine can reduce costs but that there is still inadequate reimbursement for genomic studies.

We wholeheartedly agree with the recommendation from Dr Lieberthal that more studies into the health economics of personalized medicine are urgently needed. In addition, the move towards inclusion of direct clinical trial data as the backbone of such studies would be an improvement on the current modeling algorithm approach. He eloquently visualizes the direct and indirect cost of breast cancer care and it is a stark reminder that genomic testing is only a small, but essential, gear in the patient care pathway.

Elsewhere in the Expert Insight titled [php snippet=34 param=”title=PM2.0&id=77&useTitle=true”] we discuss that in order for personalized medicine to fulfil its potential, we must start taking the long-term holistic view of health economics, rather than a short-term detrimental view, that will not fund genomic testing in the order of $100s. The cost of genomic testing pales into insignificance when compared to the potential direct and indirect cost savings of treating cancer using precision medicine.

Of course, we recognize that the fragmentation of stakeholders and inefficiencies of reimbursement systems currently supporting personalized medicine, and companion diagnostics in particular, are holding back a shift to PM2.0. However, it all starts with the data and this paper should ring alarm bells for us all given that even in breast cancer, where we now have some of the most advanced biomarker and risk assessment tools, we do not have the business model sorted out. Pity.


View all blogs

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Case Studies

View all case studies


May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
View all publications